Kerri Donahue, MD
Pulmonary Disease · Hamlin, WVNPI 1770605891
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in WV, where the typical reported total is $1,097.
Across 70 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$189
- Actelion Pharmaceuticals US, Inc.$163
- Boehringer Ingelheim$159
- AstraZeneca$152
- Amarin Pharma, Inc.$103
- Viatris Specialty LLC$60
- plus $441 from 15 others
What the payments were for
- Food & beverage$1,18994%
- Education$776%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 12 | $189 |
| Actelion Pharmaceuticals US, Inc. | 4 | $163 |
| Boehringer Ingelheim | 8 | $159 |
| AstraZeneca | 11 | $152 |
| Amarin Pharma, Inc. | 6 | $103 |
| Viatris Specialty LLC | 3 | $60 |
| Verona Pharma, Inc. | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Melinta Therapeutics, LLC | 3 | $52 |
| Insmed, Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Exact Sciences | 2 | $40 |
| Pfizer | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| BD | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Pulmonx Corporation | 1 | $16 |
| Amgen | 1 | $14 |
| Sanofi | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
How this compares
$1,266 in reported general payments places this provider in the 50th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 29 | $359,504 |
| LetairisAmbrisentan | 12 | $155,812 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $128,657 |
| Spiriva HandihalerTiotropium Bromide | 92 | $95,165 |
| Dupixent PenDupilumab | 22 | $90,275 |
| SymbicortBudesonide/Formoterol Fumarate | 97 | $48,162 |
| Incruse ElliptaUmeclidinium Bromide | 64 | $32,622 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $24,554 |
| Advair HfaFluticasone Propion/Salmeterol | 38 | $22,841 |
| Spiriva RespimatTiotropium Bromide | 25 | $17,817 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 42 | $14,795 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $14,479 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $11,049 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $11,017 |
| Arnuity ElliptaFluticasone Furoate | 27 | $9,780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $159 | $392,94381 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $189 | $210,092301 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $152 | $59,179109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Hamlin
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
- Salam RajjoubBridgeport$29K
- Peter KochupuraMorgantown$22K
- Phillip AguilaMartinsburg$21K
- Ryan WaddellCharleston$13K
- Loay Al AsadiCharleston$13K
- Vishnu PatelPrinceton$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.